rs,
51 Symbol: CONCORDBIO To General Manager, Lis ng Department BSE Limited Phiroze Jeejabhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code: 543960 Dear Sir/Ma’am, Sub.: Investor’s Presenta(ci
5%
2 Q1FY26 Key Financial Highlights Q1FY26 Key Highlights 1 2 Revenue for Q1FY26 were down by 5% on account of lumpiness in procurement pattern of our customers. The preceding quarter had excep
37%
n the previous quarter. EBIDTA margin excluding the expenses related to new facilities stands at 37% in line with EBIDTA margins for Q1FY25 5 6 Commenced commercial supply of our CDMO sales in Q2
75%
capacities Concord is well placed to capitalize on these upcoming opportunities 3 4 Acquired a 75% stake in Stellon Biotech, a US-based entity focused on marketing, distribution, and commercializa
77.6%
Q1FY26 Q1FY25 Q1FY26 Q1FY25 Q1FY26 Gross Profit Margin (%) EBIDTA Margin (%) PAT Margin (%) 77.6% 77.9% 37.7% 27.6% 30.1% 21.6% Q1FY25 Q1FY26 Q1FY25 Q1FY26 Q1FY25 Q1FY26 5 Revenue was
77.9%
Q1FY25 Q1FY26 Q1FY25 Q1FY26 Gross Profit Margin (%) EBIDTA Margin (%) PAT Margin (%) 77.6% 77.9% 37.7% 27.6% 30.1% 21.6% Q1FY25 Q1FY26 Q1FY25 Q1FY26 Q1FY25 Q1FY26 5 Revenue was down by
37.7%
Q1FY26 Q1FY25 Q1FY26 Gross Profit Margin (%) EBIDTA Margin (%) PAT Margin (%) 77.6% 77.9% 37.7% 27.6% 30.1% 21.6% Q1FY25 Q1FY26 Q1FY25 Q1FY26 Q1FY25 Q1FY26 5 Revenue was down by 5% on
27.6%
6 Q1FY25 Q1FY26 Gross Profit Margin (%) EBIDTA Margin (%) PAT Margin (%) 77.6% 77.9% 37.7% 27.6% 30.1% 21.6% Q1FY25 Q1FY26 Q1FY25 Q1FY26 Q1FY25 Q1FY26 5 Revenue was down by 5% on accoun
30.1%
25 Q1FY26 Gross Profit Margin (%) EBIDTA Margin (%) PAT Margin (%) 77.6% 77.9% 37.7% 27.6% 30.1% 21.6% Q1FY25 Q1FY26 Q1FY25 Q1FY26 Q1FY25 Q1FY26 5 Revenue was down by 5% on account of lu
21.6%
Y26 Gross Profit Margin (%) EBIDTA Margin (%) PAT Margin (%) 77.6% 77.9% 37.7% 27.6% 30.1% 21.6% Q1FY25 Q1FY26 Q1FY25 Q1FY26 Q1FY25 Q1FY26 5 Revenue was down by 5% on account of lumpiness
21%
Y26 6 Q1FY26 Segment wise Revenue Split API : Formulation (Q1FY26) Domestic : Export (Q1FY26) 21% 25% Q1FY25 Q1FY26 Q1FY25 Q1FY26 41% 41% 59% 59% 79% 75% API Formulation Domestic Exp
25%
6 Q1FY26 Segment wise Revenue Split API : Formulation (Q1FY26) Domestic : Export (Q1FY26) 21% 25% Q1FY25 Q1FY26 Q1FY25 Q1FY26 41% 41% 59% 59% 79% 75% API Formulation Domestic Exports